News
Additional Data and Trials-in-Progress Across Daiichi Sankyo’s DXd ADC Portfolio at ASCO Additional sub-analyses from the TROPION-Lung02 phase 1b trial (#8617) evaluating datopotamab deruxtecan ...
Susan Galbraith, Ph.D. (AstraZeneca) AZ and Daiichi have not yet unveiled their front-line strategy for Enhertu in HER2-low breast cancer. But AZ’s Galbraith hinted at the possibility of a more ...
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO. Late-breaking data from DESTINY-Breast09 and DESTINY-Gastric04 phase 3 ...
Daiichi Sankyo (TSE: 4568) ... June 3, 2025 from 8:00 to 9:15 am JST. Executives from Daiichi Sankyo will provide an overview of the ASCO research data and address questions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results